Physiological role of cholecystokinin in gastroprotection in humans.
OBJECTIVE
Cholecystokinin (CCK) is able to protect gastric mucosa against acute injury in experimental animals but little is known about the role of this hormone in maintaining mucosal integrity in humans. This double-blind, placebo controlled study was performed in 16 healthy volunteers. It describes the effects of CCK-8 infused intravenously (i.v.) at physiological doses and endogenous CCK released by intraduodenal (i.d.) oleate on gastric mucosal damage, as brought about by ethanol without or with pretreatment with loxiglumide, a selective CCK-A receptor antagonist.


METHODS
CCK-8 was infused i.v. 30 min before and throughout the study or i.d. oleate was instilled through a separate duodenal tube. Thirty minutes after the start of i.v. infusion of CCK or i.d. oleate instillation, 100 ml of 50% ethanol spray was applied to the gastric mucosa using an endoscope. Gastroscopy was performed and mucosal lesions were quantified using modified Lanza score. Gastric biopsies were taken from oxyntic mucosa for histological evaluation and gastric content was aspirated for radioimmunoassay of somatostatin.


RESULTS
In placebo-treated subjects ethanol caused endoscopic damage, with an average score of 2.8+/-0.2. Histologically, a widespread disruption of surface epithelium and deep hemorrhagic necrotic lesions were observed. Pretreatment with CCK or i.d. oleate markedly reduced the endoscopic lesion score to 0.7+/-0.1 and 0.3+/-0.1, respectively, and in both cases this reduction was accompanied by a significant rise in plasma CCK. Histologically, surface epithelium was still disrupted but deep necrotic lesions were absent. Gastric content collected before and after CCK or oleate showed a several-fold increase of luminally released somatostatin.


CONCLUSIONS
Pretreatment with loxiglumide abolished the protective effects of i.v. CCK-8 and i.d. oleate on mucosal lesions induced by ethanol and prevented the rise in intragastric somatostatin, but failed to affect the increments in plasma CCK. Endogenous CCK plays a physiological role in the maintenance of mucosal integrity. This occurs through activation of CCK-A receptors and is associated with an increased gastric luminal release of somatostatin.
Konturek
J W
JW
Department of Medicine B, University of Münster, Germany.
Hengst
K
K
Konturek
S J
SJ
Sito
E
E
Stachura
J
J
Domschke
W
W
D000328:Adult; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D004311:Double-Blind Method; D004386:Duodenum; D000431:Ethanol / Q000494:pharmacology; D005753:Gastric Mucosa / Q000378:metabolism; D005773:Gastroscopy; D006727:Hormone Antagonists / Q000494:pharmacology; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D019301:Oleic Acid / Q000008:administration & dosage / Q000494:pharmacology; D011377:Proglumide / Q000031:analogs & derivatives / Q000494:pharmacology; D012844:Sincalide / Q000494:pharmacology; D013004:Somatostatin / Q000378:metabolism; D013270:Stomach / Q000187:drug effects / Q000473:pathology / Q000502:physiology*
D006727:Hormone Antagonists; D019301:Oleic Acid; D000431:Ethanol; D013004:Somatostatin; C053737:loxiglumide; D002766:Cholecystokinin; D011377:Proglumide; D012844:Sincalide